medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2019, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2019; 66 (4)

Prevalence of citomegalovirus in blood donors

Barba EJR

Language: Spanish
References: 23
Page: 187-192
PDF size: 223.45 Kb.


ABSTRACT

Background and objectives: Cytomegalovirus (CMV) infection caused by transfusion (CMV-TT) can be a serious problem for immunocompromised receptors. Although the determination of anti-CMV antibodies is not mandatory as part of the tests for the detection of infectious agents transmitted by transfusion, it is important to document the prevalence of reactivity of antibodies against CMV in the blood donor group to determine the probability of transmission through blood transfusion and blood products from this virus and with it, to determine the best transfusion practices to prevent CMV-TT infection. The present study was conducted to determine the prevalence of CMV infection among blood donors by determining serum IgG and IgM anti-CMV antibodies. Material and methods: An observational, descriptive and retrospective study was carried out on 1,007 serum samples from blood donors and platelets, in which the titration of anti-CMV IgG and IgM antibodies was performed, by chemiluminescence immunoassay. Results: Of 1,007 donors, 775 men and 232 women, 724 were positive for anti-CMV IgG antibodies and 10 were positive for anti-CMV IgM antibodies. In 273 donors the IgG and IgM antibodies were non-reactive. Conclusion: The study showed statistically significant influence between age and the prevalence of anti-CMV IgG and anti-CMV IgM antibodies in blood donors, with the highest percentages being between the ages of 31 and 50 years.


REFERENCES

  1. Safabakhsh H, Karimi G, Tehranian F, Tehranian B. Demography and seroprevalence of cytomegalovirus infection in blood donors in Mashhad in 2009. J Am Sci. 2014; 10 (2): 139-142.

  2. Drew WL, Roback JD. Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion. 2007; 47: 1955-1958.

  3. Gutiérrez-Salinas J, Cruz-Tovar L. Estudio de la seroprevalencia de la infección por citomegalovirus a través de la concentración sérica de IgG en un hospital de tercer nivel. Rev Mex Patol Clin. 2008; 55 (4): 175-186.

  4. Roback JD. CMV and blood transfusions. Rev Med Virol. 2002; 12 (4): 211-219.

  5. Goldfinger D, Burner JD. You can’t get CMV from a blood transfusion: 2017 Emily Cooley award lecture. Transfusion. 2018; 58: 3038-3043.

  6. Gutiérrez-Salinas J, Carmona-García R, Cruz-Tovar L. Niveles séricos de IgG, IgM y carga viral en sujetos que presentan una infección por citomegalovirus. Enf Inf Microbiol. 2008; 28 (4): 136-141.

  7. Badami K. G. CMV and transfusions, an old story that’s not quite over yet. Int J Clin Transfus Med. 2014; 2: 7-19.

  8. Gutiérrez-Salinas J, Carmona-García R, Cruz-Tovar L. Concentraciones de IgG e IgM en pacientes con infección por citomegalovirus diagnosticada mediante PCR cualitativa. Med Int Mex. 2009; 25 (2): 105-110.

  9. Ahmed SA, Al-Joudi FS, Wan Zaidah A, Roshan TM, Rapiaah M, Abdullah YMS et al. The prevalence of human cytomegalovirus seropositivity among blood donors at the unit of blood transfusion medicine, Hospital University Sains Malaysia. Southeast Asian J Trop Med Public Health. 2006; 37 (2): 294-296.

  10. Barba-Evia JR. Citomegalovirus y trasplante renal: una combinación peligrosa. Rev Mex Patol Clin. 2006; 53 (1): 52-61.

  11. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol. 2004; 125 (2): 107-116.

  12. Vujacich C, Vidiella G, Barcelona L, Sturba E, Stamboulian D. Infección por citomegalovirus con compromiso hepático en adultos inmunocompetentes. Medicina. 2006; 66: 206-210.

  13. Hecker M, Qiu D, Marquardt K, Bein G, Hackstein H. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sanguinis. 2004; 86: 41-44.

  14. Das B, Kaur G, Basu S. Seroprevalence of cytomegalovirus antibodies among blood donors and Multitransfused recipients— a study from north India. Transfus Apher Sci. 2014; 50 (3): 438-442.

  15. Rizvi CB, Raza A, Siddiqui MF, Alam R. Sero-prevalence of human cytomegalovirus among blood donors in Lahore, Pakistan. Adv Life Sci. 2015; 2 (4): 171-175.

  16. Gutiérrez-Salinas J, Carmona-García R, García-Ortiz L, Chima-Galán MC, Suástegui-Domínguez S, Espinosa-Elizondo RM et al. Detección de infección asintomática por citomegalovirus en donadores voluntarios de sangre. Med Int Mex. 2010; 26 (2): 109-115.

  17. Rekha S, Chandrasekhara MK, Yeshwanth M. Cytomegalovirus infection acquired through blood transfusions. Indian Pediatr. 1995; 32 (5): 575-577.

  18. Benson JWT, Bodden SJ, Tobin JOH. Cytomegalovirus and blood transfusion in neonates. Archives of Disease in Childhood. 1979; 54: 538-541.

  19. Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014; 168 (11): 1054-1062.

  20. Yap PL. Transfusion transmitted viral infections-recent developments in blood donor screening. Postgrad Med J. 1990; 66: 906-909.

  21. Barbara JA, Tegtmeier GE. Cytomegalovirus and blood transfusion. Blood Rev. 1987; 1 (3): 207-211.

  22. Adler SP. Transfusion-associated cytomegalovirus infections. Rev Infect Dis. 1983; 5 (6): 977-993.

  23. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003; 101: 4195-4200.




2020     |     www.medigraphic.com